Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Nowlan

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Drugs|May 28, 2014
Albiglutide: first global approvalRaewyn M Poole, Mary L Nowlan
Drugs|July 25, 2013
Acotiamide: first global approvalMary L Nowlan, Mary L Nolan, Lesley J Scott
Arthritis and Rheumatism|September 6, 2005
Heterogeneity of tumor necrosis factor receptor-associated periodic syndrome: comment on the article by Siebert et alIan Todd, Mary L Nowlan, Elizabeth Drewe, et al.
BMJ Open|June 3, 2018
Quantifying the incidence and burden of herpes zoster in New Zealand general practice: a retrospective cohort study using a natural language processing software inference algorithmNikki M Turner, Jayden MacRae, Mary L Nowlan, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Drugs|May 28, 2014
Albiglutide: first global approvalRaewyn M Poole, Mary L Nowlan
Drugs|July 25, 2013
Acotiamide: first global approvalMary L Nowlan, Mary L Nolan, Lesley J Scott
Arthritis and Rheumatism|September 6, 2005
Heterogeneity of tumor necrosis factor receptor-associated periodic syndrome: comment on the article by Siebert et alIan Todd, Mary L Nowlan, Elizabeth Drewe, et al.
BMJ Open|June 3, 2018
Quantifying the incidence and burden of herpes zoster in New Zealand general practice: a retrospective cohort study using a natural language processing software inference algorithmNikki M Turner, Jayden MacRae, Mary L Nowlan, et al.
Pageof 1